STIMIT

About:

STIMIT enables extended local delivery of cancer immunotherapy in the context of tumor resection.

Website: https://stimittx.com/

Top Investors: Alumni Ventures, DHVC

Description:

STIMIT's proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.

Total Funding Amount:

$20.6M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)stimittx.com

Founders:

Michael Goldberg

Number of Employees:

1-10

Last Funding Date:

2020-12-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai